Shots:

• The P-III (CHOICE-01) trial evaluates toripalimab + CT vs PBO + CT in a ratio (2:1) in 465 patients with advanced sq./non-sq. NSCLC
• The interim analysis showed an improvement in OS. The study also met the 1EPs of PFS over CT alone as previously presented at WCLC 2021 while results from additional P-III studies in NSCLC, SCLC, HCC & one other indication is expected in 2022
• The companies plan to meet with US FDA to discuss sBLA submission for toripalimab + CT for advanced NSCLC & also plan to file additional toripalimab’s BLA with the US FDA for multiple other cancer over 3yrs. In 2021, Coherus gets the rights to develop and commercialize toripalimab in the US and Canada

Ref: Globe Newswire | Image: Coherus Biosciences